{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:24:20Z","timestamp":1790515460480,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Swiss National Research Foundation","award":["320030-120686"],"award-info":[{"award-number":["320030-120686"]}]},{"name":"Swiss National Research Foundation","award":["324730-144064"],"award-info":[{"award-number":["324730-144064"]}]},{"name":"Swiss National Research Foundation","award":["320030-173211"],"award-info":[{"award-number":["320030-173211"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jacl.2017.10.002","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T22:33:09Z","timestamp":1508193189000},"page":"219-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia"],"prefix":"10.1016","volume":"12","author":[{"given":"Aur\u00e9lie","family":"Delacr\u00e9taz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Gholam-Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Saigi Morgui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Glatard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Thonney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Solida-Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Kolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylfa Fassassi","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Berney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Valloton","family":"Zulauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Hasler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Ebbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"von Gunten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Conus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin B.","family":"Eap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.10.002_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1176\/ps.2009.60.2.147","article-title":"Premature mortality from general medical illnesses among persons with bipolar disorder: a review","volume":"60","author":"Roshanaei-Moghaddam","year":"2009","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jacl.2017.10.002_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.06.008","article-title":"Life expectancy among persons with schizophrenia or bipolar affective disorder","volume":"131","author":"Laursen","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jacl.2017.10.002_bib3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.002_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11920-014-0499-z","article-title":"Excess mortality in bipolar disorders","volume":"16","author":"Miller","year":"2014","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jacl.2017.10.002_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions","volume":"5","author":"Ringen","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jamapsychiatry.2013.1394","article-title":"Comorbidities and mortality in bipolar disorder: a Swedish national cohort study","volume":"70","author":"Crump","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/YCO.0b013e32835035ca","article-title":"Life expectancy and cardiovascular mortality in persons with schizophrenia","volume":"25","author":"Laursen","year":"2012","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/wps.20128","article-title":"Risks of all-cause and suicide mortality in mental disorders: a meta-review","volume":"13","author":"Chesney","year":"2014","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jamapsychiatry.2013.149","article-title":"Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit\/hyperactivity disorder participating in psychopharmacology clinical trials","volume":"70","author":"Khan","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jacl.2017.10.002_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacl.2017.10.002_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib13","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.4088\/JCP.14m09358","article-title":"Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment","volume":"76","author":"Vandenberghe","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2013.01.014","article-title":"Cardiovascular mortality in schizophrenia: defining a critical period for prevention","volume":"146","author":"Srihari","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jacl.2017.10.002_bib15","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.10.002_bib16","first-page":"1994","article-title":"Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives","volume":"4","author":"Choong","year":"2008","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.jacl.2017.10.002_bib17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib18","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1038\/tp.2015.161","article-title":"A potential mechanism underlying atypical antipsychotics-induced lipid disturbances","volume":"5","author":"Cai","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib20","first-page":"339","article-title":"Prospective 8-week trial on the effect of olanzapine, quetiapine, and aripiprazole on blood glucose and lipids among individuals with first-onset schizophrenia","volume":"26","author":"Zhang","year":"2014","journal-title":"Shanghai Arch Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/JCP.0b013e3181faf670","volume":"30","author":"Hoffmann","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jacl.2017.10.002_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/oby.2004.46","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"12","year":"2004","journal-title":"Obes Res"},{"key":"10.1016\/j.jacl.2017.10.002_bib23","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.10.002_bib24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2013.187","article-title":"Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population","volume":"70","author":"Choong","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jacl.2017.10.002_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jacl.2017.10.002_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S003329171100105X","article-title":"Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices","volume":"42","author":"Mitchell","year":"2012","journal-title":"Psychol Med"},{"key":"10.1016\/j.jacl.2017.10.002_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1359786810382056","article-title":"Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis","volume":"24","author":"Mitchell","year":"2010","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.jacl.2017.10.002_bib29","doi-asserted-by":"crossref","first-page":"e007633","DOI":"10.1136\/bmjopen-2015-007633","article-title":"Screening for the metabolic\u00a0side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK","volume":"5","author":"Barnes","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacl.2017.10.002_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1192\/bjp.bp.111.094532","article-title":"Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis","volume":"201","author":"Mitchell","year":"2012","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib32","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.10.002_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3399\/bjgp15X685933","article-title":"Cardiovascular risk assessment and lipid modification: NICE guideline","volume":"65","author":"Duerden","year":"2015","journal-title":"Br J Gen Pract"},{"issue":"Suppl 5","key":"10.1016\/j.jacl.2017.10.002_bib35","first-page":"v1","article-title":"JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice","volume":"91","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.jacl.2017.10.002_bib36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.psychres.2011.07.008","article-title":"Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder","volume":"189","author":"Bobo","year":"2011","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jacl.2017.10.002_bib37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.002_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00048670802534341","article-title":"Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls","volume":"43","author":"Elmslie","year":"2009","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jacl.2017.10.002_bib39","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1212\/WNL.45.6.1155","article-title":"Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy","volume":"45","author":"Eiris","year":"1995","journal-title":"Neurology"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417304610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417304610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:33:53Z","timestamp":1761831233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417304610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1933287417304610"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.10.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}